Abstract
Background and Objectives: Few studies have reported the drug retention rate (DRR) of biologic drugs in juvenile idiopathic arthritis (JIA), and none of them has specifically investigated the DRR of interleukin (IL)-1 inhibitors on systemic JIA (sJIA). This study aims to describe IL-1 inhibitors DRR and evaluate predictive factors of drug survival based on data from a real-world setting concerning sJIA. Methods: Medical records from sJIA patients treated with anakinra (ANA) and canakinumab (CAN) were retrospectively analyzed from 15 Italian tertiary referral centers. Results: Seventy seven patients were enrolled for a total of 86 treatment courses. The cumulative retention rate of the IL-1 inhibitors at 12-, 24-, 48-, and 60-months of follow-up was 79.9, 59.5, 53.5, and 53.5%, respectively, without any statistically significant differences between ANA and CAN (p = 0.056), and between patients treated in monotherapy compared to the subgroup co-administered with conventional immunosuppressors (p = 0.058). On the contrary, significant differences were found between biologic-naive patients and those previously treated with biologic drugs (p = 0.038) and when distinguishing according to adverse events (AEs) occurrence (p = 0.04). In regression analysis, patients pre-treated with other biologics (HR = 3.357 [CI: 1.341–8.406], p = 0.01) and those experiencing AEs (HR = 2.970 [CI: 1.186–7.435], p = 0.020) were associated with a higher hazard ratio of IL-1 inhibitors withdrawal. The mean treatment delay was significantly higher among patients discontinuing IL-1 inhibitors (p = 0.0002). Conclusions: Our findings suggest an excellent overall DRR for both ANA and CAN that might be further augmented by paying attention to AEs and employing these agents as first-line biologics in an early disease phase.
| Original language | English |
|---|---|
| Article number | 1526 |
| Journal | Frontiers in Pharmacology |
| Volume | 9 |
| Issue number | JAN |
| DOIs | |
| Publication status | Published - Jan 1 2019 |
Fingerprint
Keywords
- Anakinra
- Canakinumab
- Drug retention rate
- Interleukin 1-beta
- Systemic juvenile idiopathic arthritis
- Therapy
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
Cite this
Drug retention rate and predictive factors of drug survival for interleukin-1 inhibitors in systemic juvenile idiopathic arthritis. / Sota, Jurgen; Insalaco, Antonella; Cimaz, Rolando; Alessio, Maria; Cattalini, Marco; Gallizzi, Romina; Maggio, Maria Cristina; Lopalco, Giuseppe; Torre, Francesco La; Fabiani, Claudia; Pardeo, Manuela; Olivieri, Alma Nunzia; Sfriso, Paolo; Salvarani, Carlo; Gaggiano, Carla; Grosso, Salvatore; Bracaglia, Claudia; De Benedetti, Fabrizio; Rigante, Donato; Cantarini, Luca.
In: Frontiers in Pharmacology, Vol. 9, No. JAN, 1526, 01.01.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Drug retention rate and predictive factors of drug survival for interleukin-1 inhibitors in systemic juvenile idiopathic arthritis
AU - Sota, Jurgen
AU - Insalaco, Antonella
AU - Cimaz, Rolando
AU - Alessio, Maria
AU - Cattalini, Marco
AU - Gallizzi, Romina
AU - Maggio, Maria Cristina
AU - Lopalco, Giuseppe
AU - Torre, Francesco La
AU - Fabiani, Claudia
AU - Pardeo, Manuela
AU - Olivieri, Alma Nunzia
AU - Sfriso, Paolo
AU - Salvarani, Carlo
AU - Gaggiano, Carla
AU - Grosso, Salvatore
AU - Bracaglia, Claudia
AU - De Benedetti, Fabrizio
AU - Rigante, Donato
AU - Cantarini, Luca
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Background and Objectives: Few studies have reported the drug retention rate (DRR) of biologic drugs in juvenile idiopathic arthritis (JIA), and none of them has specifically investigated the DRR of interleukin (IL)-1 inhibitors on systemic JIA (sJIA). This study aims to describe IL-1 inhibitors DRR and evaluate predictive factors of drug survival based on data from a real-world setting concerning sJIA. Methods: Medical records from sJIA patients treated with anakinra (ANA) and canakinumab (CAN) were retrospectively analyzed from 15 Italian tertiary referral centers. Results: Seventy seven patients were enrolled for a total of 86 treatment courses. The cumulative retention rate of the IL-1 inhibitors at 12-, 24-, 48-, and 60-months of follow-up was 79.9, 59.5, 53.5, and 53.5%, respectively, without any statistically significant differences between ANA and CAN (p = 0.056), and between patients treated in monotherapy compared to the subgroup co-administered with conventional immunosuppressors (p = 0.058). On the contrary, significant differences were found between biologic-naive patients and those previously treated with biologic drugs (p = 0.038) and when distinguishing according to adverse events (AEs) occurrence (p = 0.04). In regression analysis, patients pre-treated with other biologics (HR = 3.357 [CI: 1.341–8.406], p = 0.01) and those experiencing AEs (HR = 2.970 [CI: 1.186–7.435], p = 0.020) were associated with a higher hazard ratio of IL-1 inhibitors withdrawal. The mean treatment delay was significantly higher among patients discontinuing IL-1 inhibitors (p = 0.0002). Conclusions: Our findings suggest an excellent overall DRR for both ANA and CAN that might be further augmented by paying attention to AEs and employing these agents as first-line biologics in an early disease phase.
AB - Background and Objectives: Few studies have reported the drug retention rate (DRR) of biologic drugs in juvenile idiopathic arthritis (JIA), and none of them has specifically investigated the DRR of interleukin (IL)-1 inhibitors on systemic JIA (sJIA). This study aims to describe IL-1 inhibitors DRR and evaluate predictive factors of drug survival based on data from a real-world setting concerning sJIA. Methods: Medical records from sJIA patients treated with anakinra (ANA) and canakinumab (CAN) were retrospectively analyzed from 15 Italian tertiary referral centers. Results: Seventy seven patients were enrolled for a total of 86 treatment courses. The cumulative retention rate of the IL-1 inhibitors at 12-, 24-, 48-, and 60-months of follow-up was 79.9, 59.5, 53.5, and 53.5%, respectively, without any statistically significant differences between ANA and CAN (p = 0.056), and between patients treated in monotherapy compared to the subgroup co-administered with conventional immunosuppressors (p = 0.058). On the contrary, significant differences were found between biologic-naive patients and those previously treated with biologic drugs (p = 0.038) and when distinguishing according to adverse events (AEs) occurrence (p = 0.04). In regression analysis, patients pre-treated with other biologics (HR = 3.357 [CI: 1.341–8.406], p = 0.01) and those experiencing AEs (HR = 2.970 [CI: 1.186–7.435], p = 0.020) were associated with a higher hazard ratio of IL-1 inhibitors withdrawal. The mean treatment delay was significantly higher among patients discontinuing IL-1 inhibitors (p = 0.0002). Conclusions: Our findings suggest an excellent overall DRR for both ANA and CAN that might be further augmented by paying attention to AEs and employing these agents as first-line biologics in an early disease phase.
KW - Anakinra
KW - Canakinumab
KW - Drug retention rate
KW - Interleukin 1-beta
KW - Systemic juvenile idiopathic arthritis
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=85065461877&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065461877&partnerID=8YFLogxK
U2 - 10.3389/fphar.2018.01526
DO - 10.3389/fphar.2018.01526
M3 - Article
AN - SCOPUS:85065461877
VL - 9
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
SN - 1663-9812
IS - JAN
M1 - 1526
ER -